Data as of 2026-11-14.
Lung cancer splits into two clinically distinct histologies. Non-small cell lung cancer (NSCLC) accounts for the large majority of trials and is increasingly segmented by molecular driver, EGFR, KRAS G12C, HER2, ALK, ROS1, BRAF, and RET, each with its own targeted-therapy program. Small cell lung cancer (SCLC) is a separate, faster-growing histology with a distinct trial set. A useful lung-cancer competitive picture has to track both the histology split and the molecular-subtype races at once.
Molecular-driver subtypes are subsets of NSCLC and overlap each other, so the rows below do not sum to the total above, each links to a dedicated biomarker landscape. KRAS G12C spans lung, colorectal, and pancreatic cancer; its page covers all indications.
By histology
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | 2572 | 1359 | 304 |
| Small Cell Lung Cancer (SCLC) | 504 | 280 | 56 |
By molecular driver (within NSCLC)
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| EGFR-mutant | 392 | 193 | 59 |
| KRAS G12C | 71 | 33 | 16 |
| HER2-mutant | 87 | 52 | 8 |
| ALK-positive | 73 | 28 | 8 |
| ROS1 fusion | 38 | 19 | 6 |
| BRAF V600E | 10 | 4 | 0 |
| RET fusion | 8 | 2 | 2 |
Track every new lung cancer trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.
Get the free digest, no credit cardLargest industry-sponsored lung cancer trial portfolios by active study count:
| Industry sponsor | Active trials |
|---|---|
| AstraZeneca | 103 |
| Merck (MSD) | 36 |
| Pfizer | 33 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 31 |
| Bristol-Myers Squibb | 29 |
Our pipeline pulls from ClinicalTrials.gov every day. For a lung cancer watchlist or saved search, your digest covers:
- New study registrations and status changes (for example opened to recruiting, completed)
- Protocol changes: enrollment, endpoints, phase, and completion-date movements
- New sponsor entrants into a subtype
- Phase filters (Phase 1 for novel mechanisms, Phase 3 for registration programs)
- Sponsor-type filters (large pharma vs. emerging biotech vs. academic)
Ready to automate your lung cancer trial monitoring?
Free plan, no credit card required. Set up your profile in 2 minutes.
Start freeFrequently asked questions
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, landscape reports, CSV export.
Data as of 2026-11-14, from ClinicalTrials.gov. View the full pipeline on the dashboard.